


## GSK269962A hydrochloride

Cat. No.:	HY-15556A
CAS No.:	2095432-71-4
Molecular Formula:	C <sub>29</sub> H <sub>31</sub> ClN <sub>8</sub> O <sub>5</sub>
Molecular Weight:	607.06
Target:	ROCK
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC <sub>50</sub> s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities <sup>[1]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	ROCK1 1.6 nM (IC <sub>50</sub> )	ROCK2 4 nM (IC <sub>50</sub> )	RSK1 132 nM (IC <sub>50</sub> )	MSK1 49 nM (IC <sub>50</sub> )
	AKT1 955 nM (IC <sub>50</sub> )	AKT2 1350 nM (IC <sub>50</sub> )	AKT3 1510 nM (IC <sub>50</sub> )	CDK2 3500 nM (IC <sub>50</sub> )
	GSK3α 1260 nM (IC <sub>50</sub> )			
<b>In Vitro</b>	GSK269962A has an IC <sub>50</sub> of 1.6 nM toward recombinant human ROCK1. GSK269962A exhibits more than 30-fold selectivity against a panel of serine/threonine kinases <sup>[1]</sup> . GSK269962A induces vasorelaxation in precontracted rat aorta with an IC <sub>50</sub> of 35 nM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
<b>In Vivo</b>	GSK269962A is a potent antihypertensive agent. GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	Male Sprague-Dawley rats (350-400g) <sup>[1]</sup>		
	Dosage:	0.3, 1, and 3 mg/kg		
	Administration:	Oral gavage; 12 hours		
	Result:	Induced a dose-dependent reduction in blood pressure.		

### CUSTOMER VALIDATION

- 
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

[1]. Doe C, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA